Search results
Results from the WOW.Com Content Network
MannKind (NAS: MNKD) announced breathtaking news this week -- literally. The biotech completed patient recruitment for two phase 3 clinical trials for its insulin inhalant Afrezza. The ...
MannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. Based in Danbury, Connecticut, the company was founded in February 1991. MannKind Corporation was named after its founder, Alfred E. Mann.
Biopharmaceutical company MannKind (NAS: MNKD) is seeking FDA approval for its inhalable insulin drug, Afrezza. A decision in 2013 is expected, and the company hopes to get this drug to market as ...
Biotech company MannKind (NAS: MNKD) is developing a fast-acting, inhalable insulin drug called Afrezza. The drug has previously been rejected by the FDA, but the company looks determined to ...
You could say that MannKind is treading water a bit these days -- at least from the outside perspective. The company won't announce results from its phase 3 studies of inhalable insulin Afrezza ...
Hurricane Sandy delayed the release of third-quarter results for pharmaceutical company MannKind (NAS: MNKD) , but now we know the story. MannKind beat expectations by posting a loss of $0.22 per ...
MannKind (NAS: MNKD) announced today that it licensed its preclinical BTK (Bruton's tyrosine kinase) program to Tolero Pharmaceuticals but included a take-back option in the deal. MannKind has ...
MannKind Completes Phase 3 Clinical Study of AFREZZA in Patients with Type 2 Diabetes VALENCIA, Calif.--(BUSINESS WIRE)-- MannKind Corporation (Nasdaq: MNKD) today announced that all follow-up ...